AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa
Swiss biotechnology company AB2 Bio has secured a major licensing agreement with Japanese pharmaceutical firm Nippon Shinyaku, valued at up to $686 million, for its innovative inflammatory disease treatment tadekinig alfa. The deal includes an initial payment of $36 million, with $6 million paid upfront upon signing.
The agreement centers on tadekinig alfa, a recombinant IL-18 binding protein that received FDA Breakthrough Therapy Designation in 2017. The drug targets primary monogenic IL-18 driven hyperinflammatory syndrome, a potentially fatal condition currently lacking approved treatments.
Deal Structure and Commercial Terms
Under the terms of the agreement, Nippon Shinyaku could pay up to $150 million in development milestones, followed by $500 million in commercial milestones and royalties, contingent upon successful BLA approval and marketing authorization from the FDA. The Japanese pharmaceutical company will receive exclusive commercialization rights in the United States, including Guam, Puerto Rico, and the U.S. Virgin Islands.
Scientific Mechanism and Clinical Applications
Tadekinig alfa functions by binding and inhibiting IL-18, a pro-inflammatory cytokine. In healthy individuals, naturally occurring IL-18 binding protein maintains undetectable levels of systemic free IL-18. However, in patients with autoinflammatory diseases, this balance is disrupted, leading to dangerous hyperinflammation. The drug works by restoring the IL-18 BP/IL-18 balance through capturing excess free IL-18.
Clinical Development Status
The Phase III program, with headline results expected in H1/2025, focuses on patients with verified NLRC4 or XIAP mutations who experience severe, life-threatening hyperinflammation despite symptomatic treatment. These genetic mutations result in extremely high systemic levels of IL-18, triggering immune cell hyperactivation and potential multi-organ failure.
AB2 Bio is simultaneously conducting two Phase II trials investigating tadekinig alfa in Macrophage Activation Syndrome and adult-onset Still's disease. The drug has secured Orphan Drug Designations in both Europe and the United States.
Disease Impact and Unmet Need
Primary monogenic IL-18 driven Hyperinflammatory Syndrome predominantly affects infants and young children. Without treatment, the condition can rapidly progress to multiple-organ failure and death. The disease represents a clearly defined subgroup of primary hemophagocytic lymphohistiocytosis (HLH), characterized by severe inflammatory responses and potential organ damage.
While Nippon Shinyaku gains rights for specific indications in the US market, AB2 Bio retains global rights to tadekinig alfa for all other indications, maintaining significant potential for future development and commercialization opportunities.